A study of the use of intravenous immunoglobulin on infections in patients with multiple myeloma receiving daratumumab suggested a role for the strategy in this patient population.
A study which evaluated the effect of intravenous immunoglobulin (IVIg) on infections in patients with multiple myeloma receiving daratumumab (Darzalex) presented at the 2020 American Society of Hematology (ASH) Annual Meeting & Exposition suggested that it may be especially useful in patients with recurrent infections.
In an interview with CancerNetwork®, Guido Lancman, MD, hematology and oncology fellow at the Icahn School of Medicine at Mount Sinai, explained the design of the study and what led he and his colleagues to perform the study.
Transcription:
The results show that IVIg does reduce infections in patients receiving daratumumab, but this is a retrospective study. There is a selection bias in the patients who got IVIg. What we’re going to do is we’re going to look a little bit deeper into the data to see which patients are most likely to benefit, because not necessarily all patients who get [daratumumab] will need IVIg. In this study, the patients who got IVIg, for the most part, had recurrent infections prior and [hypogammaglobulinemia].
Reference:
Lancman G, Sastow D, Aslanova M, et al. Effect of intravenous immunoglobulin on infections in multiple myeloma (MM) patients receiving daratumumab. Presented at: 2020 American Society of Hematology Annual Meeting & Exposition; December 5-8, 2020; Virtual. Paper ID #1404.
FDA Approves Cilta-Cel for Relapsed/Refractory Myeloma After 1 Therapy
April 6th 2024The FDA has approved ciltacabtagene autoleucel for the treatment of adult patients with relapsed/refractory multiple myeloma who have received at least 1 prior line of treatment, including a proteasome inhibitor and an immunomodulatory agent, and are refractory to lenalidomide.
Relapsed/Refractory Multiple Myeloma Trial Updates From ASCO 2023
August 7th 2023Experts from Mayo Clinic and The University of Texas MD Anderson Cancer Center discuss results from multiple myeloma trials presented at the 2023 American Society of Clinical Oncology Annual Meeting and how they may apply to clinical practice.